Harry Erba, MD, PhD, professor of medicine at Duke Cancer Institute, chair of the SWOG Leukemia Committee, and co-chair of ...

Texas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States Texas A&M Drug Discovery Center and Department of Chemistry, Texas A&M ...

Ascentage Pharma, a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies.

Nilotinib, a drug approved by the US Food and Drug Administration (FDA) to treat chronic myeloid leukemia, improved biomarkers and cognitive outcomes in patients with dementia with Lewy bodies ...

Snape WJ. Pathogenesis, Diagnosis, and Treatment of Acute Colonic Ileus. MedGenMed 1(3), 1999 [formerly published in Medscape Gastroenterology eJournal 1(5), 1999]. Available at: https://www ...

Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than ...

1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. 2Louis V. Gerstner Jr Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer ...